CDMO Market to Reach USD 465.24 Billion by 2032, Driven by Demand for Scalable Solutions

Contract Development and Manufacturing Organizations (CDMOs) provide end-to-end services to pharmaceutical and biotechnology companies, ranging from early-stage research through to large-scale commercial production. These organizations play a critical role in the industry by offering integrated drug development and manufacturing services. The growing demand for effective therapeutics, limited in-house manufacturing capacities, and increasing reliance of small- and mid-sized companies on outsourced production are key drivers fueling CDMO market growth.

Impact of COVID-19

The COVID-19 pandemic had a notably positive impact on the CDMO market. The urgency to develop effective treatments in 2020 accelerated drug development efforts. Pharmaceutical and biopharmaceutical companies rapidly scaled their research and production capabilities to support vaccine and therapeutic production, alongside diagnostic kits. Post-pandemic, the market experienced sustained growth, driven by renewed focus on biologics manufacturing and resumed early-phase clinical development, which had been temporarily delayed.

Strategic Collaboration: Syneos Health & P3 Research Ltd

In November 2023, Syneos Health signed an agreement with New Zealand-based P3 Research Ltd Network to expand its clinical trial capabilities across multiple therapeutic areas. This partnership further strengthened Syneos Health’s global presence and contributed to the expansion of the CDMO market.

Market Drivers

The increasing trend of outsourcing clinical trials and drug manufacturing is a major growth driver for the CDMO sector. Outsourcing allows pharmaceutical companies to reduce operational costs and avoid significant investments in infrastructure and human capital, while leveraging the specialized expertise and advanced technologies that CDMOs offer. This model enhances efficiency, flexibility, and scalability for drug development.

Regulatory Challenges

Despite the market’s strong growth prospects, regulatory compliance remains a key challenge for CDMOs. Organizations must meet stringent Good Manufacturing Practice (GMP) standards set by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These standards require rigorous validation, documentation, and quality control processes. Non-compliance may result in operational disruptions, fines, or facility shutdowns.

Industry Landscape & Competitive Outlook

Leading market players—including Boehringer Ingelheim International GmbH, IQVIA Inc., and ICON plc—are driving market growth through strategic partnerships and service expansions. For instance, in July 2024, Boehringer Ingelheim partnered with Sino Biopharmaceutical Co. Ltd. to expand its footprint in the Chinese market.

Other key players such as Unither Pharmaceuticals, Parexel International Corporation, Thermo Fisher Scientific Inc., and Vetter continue to focus on innovation and partnerships to enhance their market position and product offerings.

Key Players Profiled

• IQVIA (U.S.)
• ICON plc (Ireland)
• Syneos Health (U.S.)
• Vetter (Germany)
• Parexel International (U.S.)
• Recipharm AB (Sweden)
• Curia Global, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Unither Pharmaceuticals (France)
• DPT Laboratories, LTD. (U.S.)
• NextPharma Technologies (U.S.)
• Lonza (Switzerland)

Key Industry Development

Marionomed Biotech AG announced the successful completion of the sale of its Carragelose business to French CDMO, Unither Pharmaceuticals. This strategic acquisition is expected to strengthen Unither’s portfolio and expand its capabilities in the biologics sector.

Further Report Findings

• Service Segment Insights
  The Contract Manufacturing Organization (CMO) segment led the global CDMO market share in 2024. This dominance is primarily driven by the growing number of strategic partnerships between CDMOs and pharmaceutical/biotechnology companies aimed at accelerating therapeutic development. These collaborations continue to propel growth within the segment.

• Regional Insights
  North America emerged as the leading regional market in 2024, capturing a substantial value of USD 92.22 billion. The region’s dominance is attributed to the presence of a well-established network of CDMOs and robust partnerships with major pharmaceutical players, facilitating advanced drug development and manufacturing.

  Europe ranked as the second-largest market in 2024. The region’s growth is supported by proactive participation of industry players in medical conferences and scientific forums to enhance awareness and promote the capabilities of European CDMOs.